Roche's MASH Drug Pegozafermin Proposed for Breakthrough Therapy Designation
May 25, 2026 21:13
CST Updated
21:31
89bio
Developer of Candidate Drugs for the Treatment of Nonalcoholic Steatohepatitis
Developer of Candidate Drugs for the Treatment of Nonalcoholic Steatohepatitis